In rare cases, autoantibodies can cause severe reactions to a live-attenuated virus Chikungunya vaccine that has been discontinued in the U.S.
A new study shows that preexisting autoantibodies in a small subset of the population can allow weakened vaccine viruses to escape control, explaining some adverse events tied to one kind of Chikungunya vaccine, which is no longer available in the U.S.
Registered users, subscribers or members - SIGN IN
To continue reading this article
Membership
Included as a benefit
Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.
Find out more about how to join.
Register
FREE
Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.
Subscribe
3.75 per month / £35 annually
Get unlimited access to The Microbiologist.